Comparison of Intensive Lipid-Lowering Therapy With a Statin-Ezetimibe Combination (Without Aspirin) vs. Statin Monotherapy (With Aspirin) In Asymptomatic Patient With Coronary Artery Calcification

A Multicenter, randomized trial comparing the efficacy and safety of intensive lipid-lowering therapy using a statin-ezetimibe combination without aspirin versus statin monotherapy with aspirin in asymptomatic patients with coronary artery calcification

Start Date01 Jun 2025

Sponsor / Collaborator

Asan Medical Center

NCT06858332

/ Not yet recruitingNot Applicable

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Start Date31 Mar 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT06686615

/ Not yet recruitingNot Applicable

Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study

Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.

Start Date03 Mar 2025

Sponsor / Collaborator

Daiichi Sankyo Europe GmbH

100 Clinical Results associated with Ezetimibe

100 Translational Medicine associated with Ezetimibe

100 Patents (Medical) associated with Ezetimibe

6,344

Literatures (Medical) associated with Ezetimibe

01 May 2025·AMERICAN JOURNAL OF CARDIOLOGY

Lipid Management in United States Commercial and Medicare Enrollees With Atherosclerotic Cardiovascular Disease: Treatment Patterns and Low-Density Lipoprotein Cholesterol Control

Article

Author: N'dri, Laetitia ; Multani, Jasjit K ; Cristino, Joaquim ; Rodriguez, Fatima ; Petrilla, Allison A ; Chen, Chi-Chang ; Zhou, Zifan ; Electricwala, Batul ; Agatep, Barnabie C ; Navar, Ann Marie ; Schwartz, Taylor T

Lipid-lowering therapy (LLT) is the cornerstone for secondary prevention of atherosclerotic cardiovascular disease (ASCVD); however, many patients exhibit low adherence to therapy and fail to achieve low-density lipoprotein cholesterol (LDL-C) goals. This retrospective cohort study used 2 nationally representative closed administrative claims databases (PharMetrics Plus and Medicare Fee-for-Service Research Identifiable Files) to identify commercial and Medicare enrollees with ASCVD between 2014 and 2019. Patients were stratified by exposure to statin therapy, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (PCSK9i mAb) regimens. Outcomes included LLT adherence (proportion of days covered ≥0.8), persistence, and discontinuation at 12 months. For patients with LDL-C test results, the percentage of patients achieving LDL-C <70 mg/100 ml during follow-up was evaluated. We identified 4.6 million patients with ASCVD (commercial: 945,704; Medicare: 3,659,011), with the majority having ischemic or coronary heart disease. Of these, 66.4% commercial and 71.4% Medicare patients were on at least 1 LLT, including 69.8% commercial and 71.4% Medicare patients on statin therapy, 2.7% commercial and 1.7% Medicare patients on ezetimibe, and 0.2% commercial and 0.04% Medicare patients on a PCSK9i mAb. By 12 months, medication discontinuation was as follows: 30.4% commercial and 34.1% Medicare for statin therapy, 35.5% commercial and 46.1% Medicare for ezetimibe, and 41.5% commercial and 55.8% Medicare for PCSK9i mAb. Approximately half of the treated patients remained adherent after 12 months. Of patients with LDL-C data available (n = 381,160), <20% achieved an LDL-C <70 mg/100 ml. In conclusion, medication discontinuation and low adherence to statin, ezetimibe, and PCSK9i mAb therapies were observed in both populations. Increased efforts are needed to ensure persistence and adherence to LLT in patients with ASCVD to attain LDL-C targets.

01 May 2025·JOURNAL OF PHARMACEUTICAL SCIENCES

Ezetimibe alters micelle structure and reduces Niemann-Pick C1-like 1-mediated absorption of vitamins E and K1 in CaCo-2 cells

Article

Author: Aizawa, Hideki

Ezetimibe (EZE) is known to inhibit cholesterol absorption by targeting Niemann-Pick C1-like 1 (NPC1L1). However, its effects on the absorption of fat-soluble vitamins, such as Vitamin E and Vitamin K₁, remain unclear. This study investigates how EZE impacts micellar properties and vitamin absorption. We analyzed the shape, size, diffusion rate, and zeta-potential of micelles during Vitamin E and K₁ absorption. Our findings demonstrate that EZE causes micelles to transition from an elliptical to a cylindrical shape, reducing vitamin absorption efficiency. EZE also impairs absorption by altering micelle composition, hindering NPC1L1 binding, and directly blocking vitamin uptake. EZE negatively affects Vitamin E and K₁ absorption, raising concerns about potential deficiencies with long-term use. These findings highlight the need for strategies to minimize the adverse effects of EZE in clinical practice.

01 Apr 2025·TOXICOLOGY AND APPLIED PHARMACOLOGY

Sodium taurocholate co-transporting polypeptide deficiency attenuates acetaminophen-induced hepatotoxicity via regulating expression of drug metabolism enzymes in mice

Article

Author: Zhu, Shu ; Xu, Wenxiong ; Zhang, Yuzhen ; Yang, Fangji ; Wu, Yuankai ; Wu, Lina ; Peng, Liang ; Chong, Yutian

Acetaminophen (APAP) overdose can induce liver injury and is generally accompanied by disruption of bile acid homeostasis. Physiologically, sodium taurocholate co-transporting polypeptide (NTCP) participates in the uptake of bile acids from portal blood into hepatocytes to maintain enterohepatic recirculation but its role in APAP-induced hepatotoxicity is unclear. Wild-type (WT) C57BL/6J and NTCP knockout (KO) mice were injected with 400mg/kg APAP and liver injury was evaluated by serum biochemical markers and histologic evaluation. RNA-seq analysis was performed to evaluate the liver gene expression profiles in APAP-treated mice. Compared with WT mice, the exposure to APAP overdose caused liver dysfunction, oxidative stress, inflammation and cell death, which were ameliorated by NTCP deficiency. APAP detoxification, metabolism, and elimination were significantly accelerated by the upregulation of UDP-glucuronosyltransferase (Ugt1a1, Ugt1a6 and Ugt1a9), sulfotransferase (Sult1a1 and Sult2a1) and bile acid efflux transporters (Abcc2/3/4) in NTCP KO mice compared with WT mice. Interestingly, APAP-induced hepatotoxicity was ameliorated using Irbesartan and Ezetimibe (NTCP inhibitors). In conclusion, NTCP deficiency attenuates APAP-induced hepatotoxicity by enhancing the metabolism and elimination of APAP. NTCP inhibitors protect against APAP-induced hepatotoxicity and thus are a potential therapeutic option.

189

News (Medical) associated with Ezetimibe

31 Mar 2025

·pipelinereview.com

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, DE, USA I March 31, 2025 I Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo. 1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid lowering therapies such as statins. 1,2 These new data were presented today at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo in Chicago, Illinois, US and published simultaneously in JACC . 1,2 At 12 weeks, AZD0780 30mg taken once-daily (when added to the standard-of-care statin therapy and administered without any fasting or food restrictions) led to a 50.7% reduction in LDL-C [95% CI: -59.0%, -42.4%, p<0.001]. Similar efficacy was observed regardless of whether trial participants received moderate- or high- intensity statin doses at baseline. 1,2 In addition, AZD0780 30mg enabled 84% [95%CI: 74.4%-90.7%] of trial participants to meet their American Heart Association/American College of Cardiology guideline-recommended LDL-C target (<70 mg/dL), compared to 13% [95%CI: 7.2%-22.3%] of participants on background statin therapy alone. 1,2 High LDL-C (≥70 mg/dL), a common type of dyslipidemia, is a key risk factor for atherosclerotic cardiovascular disease, including stroke and heart attack, and a significant public health concern. 3 It is estimated that more than 70% of patients worldwide are currently not reaching guideline-recommended LDL-C targets. 4-7 Dr. Michael J Koren, MD, CEO & Medical Director of Jacksonville Center for Clinical Research, Florida, US and PURSUIT Principal Investigator, said: “The PURSUIT Phase IIb trial demonstrates the potential of AZD0780 to provide a much-needed once-daily oral treatment option to deliver greater LDL cholesterol lowering on top of standard of care for millions of patients who remain at risk for serious cardiovascular events including premature death. These results are particularly important because the majority of patients with atherosclerotic disease today do not reach their LDL-C goals, despite availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors.” Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “These new data reflect AZD0780’s ability to reduce LDL cholesterol in patients who need more options to manage their cholesterol and related risks when standard-of-care therapy is not enough. As a novel small molecule oral PCSK9 inhibitor that can be taken without fasting restrictions, AZD0780 has the potential to be a game changer that could offer LDL-C lowering with greater convenience for patients. Our work in dyslipidemia builds on our strong heritage in cardiovascular, renal and metabolic diseases where we are advancing novel therapies, alone or in combination with other molecules in our extensive portfolio, that could redefine treatment standards and patient outcomes.” AZD0780 was generally well tolerated, and adverse events (AEs) were comparable between the total AZD0780 treatment groups (38.2%) and placebo (32.6%). 1,2 The frequency of treatment discontinuations due to AEs was similar across AZD0780 (1.5%) and placebo (2.3%) groups. 1,2 Data from PURSUIT are consistent with Phase I findings presented at European Atherosclerosis Society ( EAS ) 2024. 8 Notes About Dyslipidemia Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 4.4 million deaths worldwide annually. 3 Despite current treatment options, the global burden of dyslipidemia is on the rise. 4 More than 70% of patients with atherosclerotic cardiovascular disease (ASCVD) are still not achieving their LDL-C target, so there remains a vast unmet need among high-risk patients for more varied and effective treatment options. 4-7 PURSUIT PURSUIT is a Phase IIb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of AZD0780 in participants with dyslipidemia. 2 PURSUIT assessed the efficacy, safety and tolerability of different doses of AZD0780 on LDL-C levels in patients with hypercholesterolemia. 428 patients on stable standard-of-care therapy with moderate- or high-intensity statins with or without ezetimibe with LDL-C levels ≥70 and <190 mg/dL were randomized (1:1:1:1:1) to receive AZD0780 (1 mg, 3 mg, 10 mg and 30 mg daily) or matching placebo. 426 patients started treatment. 2 The primary objective of the study was to measure the effect of different doses of AZD0780 given once daily on LDL-C levels in patients with dyslipidemia receiving standard-of-care statins. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers was also investigated. The concentration of AZD0780 in blood at specific timepoints was measured, and the safety and tolerability of AZD0780 evaluated. 2 AZD0780 AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels which cannot be controlled by statins alone. 2 PCSK9 is a well-known and validated target in LDL-C metabolism and inhibiting PCSK9 signalling has shown to be effective in reducing LDL-C levels in plasma. 2 Lower LDL-C levels are associated with a reduction in the risk of long-term cardiovascular disease and major cardiovascular events. 9 AstraZeneca is investigating the potential of AZD0780 as an oral small-molecule for use as a monotherapy or in fixed-dose combinations with other therapies in our extensive portfolio. Data from PURSUIT are consistent with Phase I findings for AZD0780 which demonstrated a statistically significant reduction of 51% in LDL-C levels on top of rosuvastatin treatment, with 80% total reduction from baseline, in treatment-naive participants with hypercholesterolemia. 2 AstraZeneca in CVRM Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively. AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca . References SOURCE: AstraZeneca

Clinical ResultPhase 2Phase 1AHA

31 Mar 2025

·www.fiercebiotech.com

AstraZeneca\'s oral PCSK9 inhibitor halves cholesterol in phase 2 trial

A total of 84% of patients who received the 30 mg dose were able to meet AHA-recommended LDL-C levels.\n The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder.The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can progress to clogged arteries, known as atherosclerosis.AstraZeneca used the American College of Cardiology conference today to unveil data from a phase 2 study of 428 patients with the condition who received one of four doses of AZD0780 or placebo, along with standard-of-care statin therapy and, in some cases, the approved high cholesterol drug ezetimibe.The highest daily dose, 30 mg, of AZD0780 was tied to a 50.7% reduction in low-density lipoprotein cholesterol (LDL-C) at 12 weeks. Around this level of efficacy was observed regardless of whether patients were also receiving moderate or high-intensity statin doses alongside AZD0780, AstraZeneca noted.A total of 84% of patients who received the 30 mg dose were able to meet the American Heart Association guidelines of having LDL-C levels under 79 mg/dL, compared to 13% of those on placebo.The rate of adverse events in the combined AZD0780 treatment groups was 38.2%, compared to 32.6% in the placebo cohort. The frequency of treatment discontinuations due to these events was 1.5% for the investigational arm and 2.3% for placebo. “These new data reflect AZD0780’s ability to reduce LDL-cholesterol in patients who need more options to manage their cholesterol and related risks when standard of care therapy is not enough,” Sharon Barr, AstraZeneca\'s executive vice president of biopharmaceuticals R&D, said in a release.“As a novel small molecule oral PCSK9 inhibitor that can be taken without fasting restrictions, AZD0780 has the potential to be a game changer that could offer LDL-C lowering with greater convenience for patients,” Barr added.The phase 2 results echo an early-stage readout for AZD0780 last year that showed a similar 52% reduction in LDL-C.The hypercholesterolemia market is currently dominated by injectable PCSK9 inhibitors in the form of Amgen’s Repatha and Sanofi-Regeneron’s Praluent. Meanwhile, Novartis’ Leqvio uses small-interfering RNA technology to decrease PCSK9 production in the liver.AstraZeneca’s attempt to get an oral option to patients in the form of AZD0780 remains behind Merck & Co.’s own oral PCSK9 inhibitor MK-0616, which is already undergoing a slate of phase 3 trials to confirm its LDL-C-lowering capabilities.In today’s release, Michael Koren, M.D., CEO and medical director of the Jacksonville Center for Clinical Research in Florida, said the results for AZD0780 are “particularly important because the majority of patients with atherosclerotic disease today do not reach their LDL-C goals, despite availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors.”

$AstraZeneca\'s oral PCSK9 inhibitor halves cholesterol in phase 2 trial$

Phase 2Clinical ResultPhase 3AHAsiRNA

25 Mar 2025

·www.drugs.com

Two-Drug Combo of a Statin Plus Ezetimibe, Lowers Cholesterol Better Than Statins Alone

TUESDAY, March 25, 2025 -- Statins are very cheap and highly effective cholesterol-lowering drugs -- but high-risk heart patients may have an even better option, a new evidence review says. Combining statins with another drug, ezetimibe , significantly reduces the risk of death in patients with clogged arteries, according to findings published March 23 in Mayo Clinic Proceedings . Using a high-dose statin with ezetimibe significantly reduces levels of “bad” LDL cholesterol, increasing a person’s chances of reaching healthy levels by 85%, researchers found. The combo also brought about a 19% reduction in risk of death from any cause; a 16% reduction in heart-related deaths; an 18% decrease in the risk of a major cardiovascular health problem; and a 17% decline in stroke risk. This combination therapy would prevent more than 330,000 deaths a year worldwide among patients who have already suffered a heart attack, including almost 50,000 deaths in the U.S. alone, researchers said. “This study confirms that combined cholesterol lowering therapy should be considered immediately and should be the gold standard for treatment of very high-risk patients after an acute cardiovascular event,” senior researcher Dr. Peter Toth , a professor of clinical family and community medicine at the University of Illinois, said in a news release. Up to now, studies have been inconsistent regarding whether to provide combo cholesterol-lowering therapy immediately for high-risk patients, even before they suffer a heart attack or stroke . Typically, doctors wait at least two months before adding any medication to a statin, to see how well statins alone will lower cholesterol, Toth said. “This approach does not require additional funding or reimbursement of new expensive drugs,” he said. “In fact, it may translate into lower rates of first and subsequent heart attacks and stroke, and their complications like heart failure, which are extremely costly for all healthcare systems.” For the new evidence review, researchers pooled data from 14 studies involving more than 108,000 heart patients at very high risk for a heart attack, stroke or other heart-related health problem. Results were even more pronounced in an additional analysis that enabled a direct comparison of different therapies, researchers said. “This showed a 49% reduction in all-cause mortality and a 39% reduction in major adverse cardiovascular events, when compared to high dose statin therapy alone,” said lead researcher Dr. Maciej Banach , a professor of cardiology at the John Paul II Catholic University of Lublin in Poland. Ezetimibe works by reducing the amount of cholesterol the intestines can absorb from food. Statins have a different mechanism – they work by interfering with the liver’s ability to make cholesterol. Both drugs are available as inexpensive generics. “Our findings underline the importance of the adages ‘the lower for better for longer’ but also the equally important ‘the earlier the better’ for treating patients at high risk of cardiovascular conditions and to avoid further medical complications and deaths,” Toth said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHAClinical Result

100 Deals associated with Ezetimibe

External Link

KEGG	Wiki	ATC	Drug Bank
D01966	Ezetimibe	C10AX09	DB00973

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperlipidemias	United States	Organon & Co.	05 Jun 2008
Hypercholesterolemia	United States	Organon & Co.	23 May 2006
Cardiovascular Diseases	Australia	Organon Pharma Pty Ltd.	23 Jun 2003
Heterozygous familial hypercholesterolemia	Australia	Organon Pharma Pty Ltd.	23 Jun 2003
Homozygous familial hypercholesterolemia	United States	Organon & Co.	25 Oct 2002
Primary hypercholesterolemia	United States	Organon & Co.	25 Oct 2002
Sitosterolemia	United States	Organon & Co.	25 Oct 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Sep 2009
Hyperlipidemia, Familial Combined	Phase 3	-	Organon & Co.	01 Dec 2002
Hypertriglyceridemia	Phase 3	-	Organon & Co.	01 Dec 2002
Atherosclerosis	Phase 3	-	Organon & Co.	01 Jun 2002
Hyperlipoproteinemia Type II	Phase 3	-	Organon & Co.	01 Jun 2002
Diabetes Mellitus, Type 2	Phase 3	-	Organon & Co.	01 Dec 2001
Coronary Disease	Phase 3	-	Organon & Co.	24 Apr 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04826354 (SaveSAMS, Pubmed) Manual	Phase 4	Atherosclerosis	561	Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 5 mg with ezetimibe 10 mg)	xftczjuejv(txgkrqklgc) = tzcjfgfbng wtscpcygyr (ytnjbaeeyx ) View more	Positive	22 Dec 2024
				High-intensity statin monotherapy (rosuvastatin 20 mg)	xftczjuejv(txgkrqklgc) = jqmlgfrcjr wtscpcygyr (ytnjbaeeyx ) View more
NCT04369664 (CHORD, CTgov)	Phase 4	Diabetes Mellitus, Type 2	151	PCSK9 inhibitor+Ezetimibe 10mg+Statin (Type 2 Diabetes Group)	cdklsxzgkj(nlxvkecyyn) = mphfxrfftu vvdhbtwzhl (zlvvyvrdvp, jbqjhugckp - otzttsdvmt) View more	-	17 Oct 2024
				PCSK9 inhibitor+Ezetimibe 10mg+Statin (Control Group)	cdklsxzgkj(nlxvkecyyn) = nqunbloxkj vvdhbtwzhl (zlvvyvrdvp, oakyjdiidu - xpekqqacjb) View more
ESC2024	Not Applicable	Myocardial Infarction	-	Ezetimibe use	fsqraplzne(uqyozhcjbl) = sxcsgdgmhd aznemyvfzf (adffglvmqd )	Positive	31 Aug 2024
				No Ezetimibe use	fsqraplzne(uqyozhcjbl) = lbzeequuyo aznemyvfzf (adffglvmqd )
ATS2024	Not Applicable	Idiopathic Pulmonary Fibrosis	-	Ezetimibe users	lexadzzhre(vgtqkwwdqs) = stnufmbvsf yahkgfiwbk (utuokcomsu )	Positive	19 May 2024
				Non-users	lexadzzhre(vgtqkwwdqs) = bffhcloqmg yahkgfiwbk (utuokcomsu )
NCT04638400 (CTgov)	Phase 4	Inflammation \| Atherosclerosis \| Obesity ... View more	10	Simvastatin 40mg (Simvastatin)	lncappwuyb(gxhxtrlnsv) = anjjyhxwkc juasvxtlea (aeplrepilv, 11) View more	-	23 Jan 2024
				Ezetimibe 10mg (Ezetimibe)	lncappwuyb(gxhxtrlnsv) = mystzgupbs juasvxtlea (aeplrepilv, 7) View more
NCT00988364 (Merck-123, CTgov)	Phase 4	Metabolic Syndrome	30	ezetimibe (Ezetimibe)	nfenkxodds(bhgvyrmdgu) = cnlacpsusx yyjzopepvw (zozfhuiatf, 28.87) View more	-	30 Nov 2023
				Simvastatin (Simvastatin)	nfenkxodds(bhgvyrmdgu) = dtfgbzcqzm yyjzopepvw (zozfhuiatf, 14.4558) View more
AASLD2023	Not Applicable	-	88	Glecaprevir/pibrentasvir + Ezetimibe	jjcwhcklgh(ctrjeqcetu) = 27 (46%) patients developed HCV antibodies that persisted post-treatment tnuvdaekgi (nxdcfmxczg )	-	10 Nov 2023
FRI094 (ENDO2023)	Not Applicable	Sitosterolemia	1	Ezetimibe 20 mg daily	pebiepnkdc(qgbcvatawu) = wvjypolmep wmzdsufill (sfflayddgv ) View more	Positive	05 Oct 2023
				Atorvastatin 20 mg daily	pebiepnkdc(qgbcvatawu) = wrbmqmbnye wmzdsufill (sfflayddgv ) View more
IMPROVE-IT (ESC2023)	Not Applicable	-	-	Ezetimibe	jlouzsimwc(ewfqbyhkub): RR = 0.77 (95% CI, 0.62 - 0.96), P-Value = 0.018	Positive	26 Aug 2023
				Placebo
ADA2023	Not Applicable	Diabetes Mellitus, Type 2	-	Moderate-intensity statin with ezetimibe combination therapy	wnlfaepaqz(ipfrchwndm): HR = 0.7 (95% CI, 0.52 - 0.93), P-Value = 0.014 View more	Positive	20 Jun 2023
				High-intensity statin monotherapy

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis